Vermillion Announces Issuance of Patent for Lung Cancer

AUSTIN, Texas, Sept. 6, 2011 /PRNewswire via COMTEX/ -- Vermillion, Inc. /quotes/zigman/109541/quotes/nls/vrml VRML -8.08% , a molecular diagnostics company, today announced that the United States Patent and Trademark Office (USPTO) has issued patent number 8,014,952 entitled " Serum Biomarkers in Lung Cancer " to the Company.

"This patent highlights on-going progress in expanding our intellectual property portfolio. Beyond our core focus areas of ovarian cancer and peripheral artery disease, we now have patents in lung cancer, breast cancer, and Alzheimer's disease. It is our goal to explore business opportunities to leverage this growing and valuable asset of the Company," said Gail S. Page, CEO of Vermillion.

About Vermillion:

Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in oncology, hematology, cardiology and women's health. Additional information about Vermillion can be found on the Web at www.vermillion.com .

Suggested Articles

Xevinapant in combination with standard cisplatin-based chemoradiation therapy (CRT) reduces the risk of death in high-risk patients with locally adva

Ironwood had once hyped this drug as a $2 billion-a-year asset, but IW-3718 has failed to live up to its high expectations.

Junshi’s PD-1 blocker is already approved in China for metastatic melanoma, but the Shanghai-based biotech may soon add throat cancer to its label.